What the changes say
- MYQORZO’s December 2025 approval shifts risk toward commercialization, including market acceptance, REMS compliance, manufacturing and profitability.
- Single-source manufacturers must supply MYQORZO, including aficamten for Sanofi and Bayer’s China, Taiwan and Japan programs.
- Newly highlighted threats include FDA disruptions, a potential HCM patent, healthcare price controls and broad litigation.
- Several financing, debt, manufacturing-capability, trade-secret and internal-control risks were removed or consolidated.
What changed since the prior 10-K
New
- New
In addition, under our license and collaboration agreements, we have committed to providing Sanofi and Bayer with supply of aficamten for development and commercialization of MYQORZO in China, Taiwan and Japan, which we will have to source from our contract manufacturers
Single-source contract manufacturers must supply MYQORZO, including aficamten for Sanofi and Bayer’s China, Taiwan and Japan commercialization programs.
- New
Approved drug products remain subject to ongoing obligations, including continued regulatory review by the FDA and foreign regulatory agencies and REMS, all of which may result in significant expense and limit commercialization efforts of our drugs
MYQORZO’s FDA approval carries extensive REMS requirements and pregnancy and lactation post-marketing studies that could increase costs and restrict commercialization.
- New
Disruptions at the FDA, including due to a reduction in the FDA’s workforce and/or inadequate funding for the FDA, could prevent the FDA from performing normal functions on which our business relies, which could negatively impact our business
FDA workforce reductions, funding shortfalls or government shutdowns could delay MYQORZO and drug-candidate submissions, inspections, guidance and approvals.
- New
Infringement lawsuits are costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business, including our ability to market MYQORZO to the fullest extent permissible within regulatory approvals
A potentially issuable third-party patent on cardiac myosin inhibitors could be asserted against certain HCM treatment methods involving MYQORZO.
- NewFinancial Risks
Our ability to use net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be subject to certain limitations, and ownership changes may limit our ability to use our net operating losses and tax credits in the future
Ownership changes could restrict use of federal and state NOLs and tax credits, increasing future taxes despite no Section 382 change through 2025.
- NewLegal and Compliance Risks
We cannot be sure whether additional legislation or rulemaking related to these developments will be issued or enacted, or what impact, if any, such changes will have on the profitability of MYQORZO, or any of our drug candidates, if approved for commercial use, in the future
Future healthcare legislation, price controls or reimbursement cuts could reduce MYQORZO demand, sales and achievable pricing.
- NewLegal and Compliance Risks
Litigation may substantially increase our costs and harm our business
Lawsuits involving directors, stockholders, intellectual property or employment matters could impose legal costs, distract management and produce adverse financial outcomes.
Dropped
- Dropped
Risks Specific to our Company in connection with our Research and Development Activities
Risks specific to research and development activities.
- Dropped
Risks Specific to our Company in connection with our Commercial Operations
- Dropped
We have no manufacturing capabilities and depend on contract manufacturers to produce our clinical trial materials, including our drug candidates, and will have continued reliance on contract manufacturers for the development and commercialization of our potential drugs
- Dropped
If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed
- Dropped
If we are sued for infringing third-party intellectual property rights, it will be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business
- Dropped
We may undertake infringement or other legal proceedings against third parties, causing us to spend substantial resources on litigation and exposing our own intellectual property portfolio to challenge
Difficulty estimating market size for aficamten and other drug candidates.
- Dropped
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that we or our employees have wrongfully used or disclosed trade secrets of their former employers
- DroppedFinancial Risks
As of December 31, 2024 and 2023 we had $0.8 billion and $0.6 billion of debt recorded on the balance sheet comprised of the RP Multi Tranche Loan Agreement, the RP OM Loan Agreement, and the 2026 and 2027 Convertible Notes, respectively
- DroppedFinancial Risks
We may not be entitled to obtain additional loan disbursements under the RP Multi Tranche Loan Agreement
Dependence on contract manufacturers because the company lacks manufacturing facilities and capabilities.
- DroppedFinancial Risks
Any material limitation or expiration of our NOLs and tax credit carryforwards may harm our future net income by effectively increasing our future effective tax rate, which could result in a reduction in the market price of our common stock
- DroppedFinancial Risks
We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting
Reworded
- 86% rewritten
If physicians and patients do not accept our drugs, we may be unable to generate significant revenue, if any
The risk now specifically names MYQORZO as potentially lacking acceptance, while applying the same concern to other candidates if approved.
- 77% rewritten
Clinical trials could fail to demonstrate the desired safety and efficacy of our drug candidates, which could prevent or significantly delay completion of clinical development and regulatory approval
The text reflects MYQORZO’s December 2025 approval and the company’s past failure to meet FDA and other regulators’ safety and efficacy standards.
Was: Clinical trials may fail to demonstrate the desired safety and efficacy of our drug candidates, which could prevent or significantly delay completion of clinical development and regulatory approval
- 68% rewrittenFinancial Risks
We will need substantial additional capital in the future to sufficiently fund and maintain our operations
Funding is increasingly expected to come from MYQORZO commercial sales rather than historical financing sources, although existing resources are projected to last 12 months.
- 59% rewritten
We may not be able to successfully manufacture our drugs or drug candidates in sufficient quality and quantity, which would delay or prevent us from developing our drug candidates and commercializing approved drug products
The risk now covers commercial-scale manufacturing for approved MYQORZO, rather than only manufacturing drug candidates for clinical development.
Was: We may not be able to successfully manufacture our drug candidates in sufficient quality and quantity, which would delay or prevent us from developing our drug candidates and commercializing approved drug products, if any
- 56% rewritten
Our success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our drug candidates, compounds and research technologies
The protection concern now expressly covers marketed drugs as well as drug candidates, compounds and research technologies.
- 46% rewrittenFinancial Risks
We have a history of significant losses and may not achieve or sustain profitability and, as a result, you may lose part or all of your investment
The update notes MYQORZO’s December 2025 approval and initial commercialization, while shifting remaining development and profitability risks to other candidates and MYQORZO acceptance.
- 40% rewrittenFinancial Risks
We will depend on Sanofi for the development and commercialization of aficamten in China and Bayer for the development and commercialization of aficamten in Japan
Sanofi’s and Bayer’s territories are tied to aficamten’s MYQORZO commercialization, with the risk now omitting some detailed partner-obligation examples.
- 36% rewritten
Our competitors may develop drugs that are less expensive, safer and/or have similar or better efficacy than ours, which may diminish or eliminate the commercial success of any drugs that we may commercialize
The risk now describes competitors as actively developing competing drugs, rather than primarily warning that they may develop them.
- 31% rewrittenGeneral Risk Factors
Significant disruptions of information technology systems or breaches of data security could adversely affect our business
- 26% rewritten
The commercial success of our products depends on the availability and sufficiency of third‑party payor and/or government for coverage and reimbursement
Was: The commercial success of our products depends on the availability and sufficiency of third‑party payor coverage and reimbursement
- 26% rewritten
The regulatory approval and marketing authorization process is expensive, time-consuming and uncertain and may prevent our partners or us from obtaining approvals to commercialize some or all of our drug candidates
All 29 risk factors
Headings as the filing states them, in filing order.
Other
- 01If physicians and patients do not accept our drugs, we may be unable to generate significant revenue, if any86% rewritten
- 02Our competitors may develop drugs that are less expensive, safer and/or have similar or better efficacy than ours, which may diminish or eliminate the commercial success of any drugs that we may commercialize36% rewritten
- 03The commercial success of our products depends on the availability and sufficiency of third‑party payor and/or government for coverage and reimbursement26% rewritten
- 04In addition, under our license and collaboration agreements, we have committed to providing Sanofi and Bayer with supply of aficamten for development and commercialization of MYQORZO in China, Taiwan and Japan, which we will have to source from our contract manufacturersNew
- 05We may not be able to successfully manufacture our drugs or drug candidates in sufficient quality and quantity, which would delay or prevent us from developing our drug candidates and commercializing approved drug products59% rewritten
- 06Approved drug products remain subject to ongoing obligations, including continued regulatory review by the FDA and foreign regulatory agencies and REMS, all of which may result in significant expense and limit commercialization efforts of our drugsNew
- 07The regulatory approval and marketing authorization process is expensive, time-consuming and uncertain and may prevent our partners or us from obtaining approvals to commercialize some or all of our drug candidates26% rewritten
- 08Disruptions at the FDA, including due to a reduction in the FDA’s workforce and/or inadequate funding for the FDA, could prevent the FDA from performing normal functions on which our business relies, which could negatively impact our businessNew
- 09Clinical trials could fail to demonstrate the desired safety and efficacy of our drug candidates, which could prevent or significantly delay completion of clinical development and regulatory approval77% rewritten
- 10If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
- 11The failure to successfully develop, manufacture and obtain regulatory clearance or approval of an immunoassay or companion diagnostics, if required by FDA as a condition to approval of our drugs, could harm our development and commercialization strategy for such drugs in key markets
- 12Our success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our drug candidates, compounds and research technologies56% rewritten
- 13Infringement lawsuits are costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business, including our ability to market MYQORZO to the fullest extent permissible within regulatory approvalsNew
Financial Risks
- 14We have a history of significant losses and may not achieve or sustain profitability and, as a result, you may lose part or all of your investment46% rewritten
- 15We will need substantial additional capital in the future to sufficiently fund and maintain our operations68% rewritten
- 16Conversion of our outstanding Convertible Notes may result in the dilution of existing stockholders, create downward pressure on the price of our common stock, and restrict our ability to take advantage of future opportunities
- 17We will depend on Sanofi for the development and commercialization of aficamten in China and Bayer for the development and commercialization of aficamten in Japan40% rewritten
- 18Our ability to use net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be subject to certain limitations, and ownership changes may limit our ability to use our net operating losses and tax credits in the futureNew
Legal and Compliance Risks
- 19We cannot be sure whether additional legislation or rulemaking related to these developments will be issued or enacted, or what impact, if any, such changes will have on the profitability of MYQORZO, or any of our drug candidates, if approved for commercial use, in the futureNew
- 20We cannot predict the likelihood, nature, or extent of health reform initiatives that may arise from future legislation or administrative action and cannot predict the effect of any of such initiatives on our future financial results or the value of our common stock
- 21We may be subject to costly product liability or other liability claims and may not be able to obtain adequate insurance
- 22We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us
- 23Responding to any claims relating to improper handling, storage or disposal of the hazardous chemicals and radioactive and biological materials we use in our business could be time-consuming and costly
- 24Litigation may substantially increase our costs and harm our businessNew
General Risk Factors
- 25Our failure to attract and retain skilled personnel could impair our drug development, commercialization and financial reporting activities
- 26Significant disruptions of information technology systems or breaches of data security could adversely affect our business31% rewritten
- 27Our facilities in California are located near an earthquake fault, and an earthquake or other types of natural disasters, catastrophic events or resource shortages could disrupt our operations and adversely affect our results
- 28We expect that our stock price will fluctuate significantly, and you may not be able to resell your shares at or above your investment price
- 29Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management
Other Cytokinetics 10-Ks
- FY2024 10-K risk factors33 risks
Clinical and regulatory failure could prevent approval of aficamten and other drug candidates.
Filed Feb 27, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.